What changed from existing technology?
This study uses artificial intelligence to find and create better ways to display proteins on cell surfaces, which could help in developing vaccines and other medical treatments.
This is the first study to use deep learning and AI models to systematically map the relationship between CSD sequence and function, enabling the design of potent de novo CSD modules for mRNA antigen display.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
s are a major class of bioengineering modules, but systematic rules linking CSD sequence to functional potency are lacking. Here we develop DeepSCan, a s
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Early research
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The DeepSCan models could be used to design and optimize cell surface display modules for mRNA-based vaccines and therapeutic proteins, improving their stability and immunogenicity.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.